Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive Real-World study to see if targeted pills boost survival after lung cancer surgery

NCT ID NCT07593248

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 5 times

Summary

This observational study will follow about 2,000 patients in China who have early-stage lung cancer with a specific gene mutation (EGFR) and have received targeted therapy pills (EGFR-TKIs) after surgery. Researchers will track how long patients live and how long they stay cancer-free over five years. The goal is to see how well these drugs work in everyday medical practice, outside of controlled clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
EGFR-TKI (a type of targeted therapy pill)
What this could lead to
If successful, this study could provide real-world evidence on how well EGFR-TKIs work as an add-on treatment after surgery for early-stage lung cancer, potentially guiding future treatment decisions.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient differences and cannot prove cause and effect. It only includes patients in China, so findings may not apply globally.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jun 2031

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

stage IB to III NSCLC who have received adjuvant EGFR-TKI therapy.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed stage IB-III NSCLC on or prior to the index date; * Initiated adjuvant EGFR-TKI from July 1st, 2023 to June 30th, 2026

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    14 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    NOT_YET_RECRUITING

    Beijing, China

  • Research Site

    NOT_YET_RECRUITING

    Chengdu, China

  • Research Site

    NOT_YET_RECRUITING

    Fuzhou, China

  • Research Site

    RECRUITING

    Guangzhou, China

  • Research Site

    NOT_YET_RECRUITING

    Guangzhou, China

  • Research Site

    NOT_YET_RECRUITING

    Nanchang, China

  • Research Site

    NOT_YET_RECRUITING

    Shanghai, China

  • Research Site

    NOT_YET_RECRUITING

    Shenyang, China

  • Research Site

    NOT_YET_RECRUITING

    Shijiazhuang, China

  • Research Site

    NOT_YET_RECRUITING

    Tianjin, China

  • Research Site

    NOT_YET_RECRUITING

    Wuhan, China

  • Research Site

    NOT_YET_RECRUITING

    Xi'an, China

  • Research Site

    NOT_YET_RECRUITING

    Xuzhou, China

  • Research Site

    NOT_YET_RECRUITING

    Zhengzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.